Part of our new generation of adjuvants, CAF01 is a liposomal adjuvant formulation that offers excellent long-term stability and drives both humoral and cellular immune responses.
CAF01 is a fully synthetic liposome-based adjuvant system developed by Statens Serum Institut (SSI.) It is comprised of DDA, a cationic quaternary ammonium salt, and the glycolipid TDB.
CAF01 is known for long-term protection and immunological memory, due to its power to elicit potent Th1 and Th17 responses. CAF01 induces systemic immunity, facilitating mucosal booster responses after the administration of antigens alone.
Liposomes have notable benefits when used as vaccine delivery systems. Their spherical structures and capacity for targeted delivery can help enhance drug effectiveness and reduce side effects. Above all, they can create more potent and effective vaccines when used in combination with other adjuvants.
CAF01 is used in several ongoing clinical vaccine trials, including for tuberculosis, chlamydia, HIV, and malaria.
Our CAF range (including CAF09b) offers opportunities for new prophylactic and therapeutic vaccines. Our exclusive partnership with SSI enables you to access these patented formulations for your development needs.
Finding the right type of adjuvant for your needs requires a discussion. Contact us to get access to this unique technology.
CAF01 is a fully synthetic liposome-based adjuvant system developed by Statens Serum Institut (SSI.) It is comprised of DDA, a cationic quaternary ammonium salt, and the glycolipid TDB.
CAF01 is known for long-term protection and immunological memory, due to its power to elicit potent Th1 and Th17 responses. CAF01 induces systemic immunity, facilitating mucosal booster responses after the administration of antigens alone.
Liposomes have notable benefits when used as vaccine delivery systems. Their spherical structures and capacity for targeted delivery can help enhance drug effectiveness and reduce side effects. Above all, they can create more potent and effective vaccines when used in combination with other adjuvants.
CAF01 is used in several ongoing clinical vaccine trials, including for tuberculosis, chlamydia, HIV, and malaria.
Our CAF range (including CAF09b) offers opportunities for new prophylactic and therapeutic vaccines. Our exclusive partnership with SSI enables you to access these patented formulations for your development needs.
Finding the right type of adjuvant for your needs requires a discussion. Contact us to get access to this unique technology.
Product details
Chemical group
- Liposome
Administration route
- Vaccine adjuvant
Market application
- Human vaccines
- Veterinary vaccines
Functions
- Vaccine adjuvant
Physical form
- Gel-phase